Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher Gallagher

Showing results (101-110 of 108) with videos related to

Pageof 11
Sort By:
You have reached the last page of results.This site can display upto 108 results.
JCO Oncology Practice|August 10, 2021
Evaluation of the Novel 4R Oncology Care Planning Model in Breast Cancer: Impact on Patient Self-Management and Care Delivery in Safety-Net and Non-Safety-Net CentersJulia R Trosman, Christine B Weldon, Bruce D Rapkin, et al.
Journal of Graduate Medical Education|August 22, 2017
Results of a Flipped Classroom Teaching Approach in Anesthesiology ResidentsSusan M Martinelli, Fei Chen, Amy N DiLorenzo, et al.
European Journal of Nutrition|October 27, 2021
Individual participant data (IPD)-level meta-analysis of randomised controlled trials to estimate the vitamin D dietary requirements in dark-skinned individuals resident at high latitudeKevin D Cashman, Mairead E Kiely, Rikke Andersen, et al.
Nature Communications|March 28, 2024
Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II studyFilipa Lynce, Candace Mainor, Renee N Donahue, et al.
Nature Communications|May 10, 2024
Author Correction: Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II studyFilipa Lynce, Candace Mainor, Renee N Donahue, et al.
Medrxiv : the Preprint Server for Health Sciences|December 18, 2023
Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II studyFilipa Lynce, Candace Mainor, Renee N Donahue, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 15, 2021
BRE12-158: A Postneoadjuvant, Randomized Phase II Trial of Personalized Therapy Versus Treatment of Physician's Choice for Patients With Residual Triple-Negative Breast CancerBryan P Schneider, Guanglong Jiang, Tarah J Ballinger, et al.
JAMA Oncology|July 10, 2020
Association of Circulating Tumor DNA and Circulating Tumor Cells After Neoadjuvant Chemotherapy With Disease Recurrence in Patients With Triple-Negative Breast Cancer: Preplanned Secondary Analysis of the BRE12-158 Randomized Clinical TrialMilan Radovich, Guanglong Jiang, Bradley A Hancock, et al.
Pageof 11

Showing results (101-110 of 108) with videos related to

Sort By:
Pageof 11
You have reached the last page of results.This site can display upto 108 results.
JCO Oncology Practice|August 10, 2021
Evaluation of the Novel 4R Oncology Care Planning Model in Breast Cancer: Impact on Patient Self-Management and Care Delivery in Safety-Net and Non-Safety-Net CentersJulia R Trosman, Christine B Weldon, Bruce D Rapkin, et al.
Journal of Graduate Medical Education|August 22, 2017
Results of a Flipped Classroom Teaching Approach in Anesthesiology ResidentsSusan M Martinelli, Fei Chen, Amy N DiLorenzo, et al.
European Journal of Nutrition|October 27, 2021
Individual participant data (IPD)-level meta-analysis of randomised controlled trials to estimate the vitamin D dietary requirements in dark-skinned individuals resident at high latitudeKevin D Cashman, Mairead E Kiely, Rikke Andersen, et al.
Nature Communications|March 28, 2024
Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II studyFilipa Lynce, Candace Mainor, Renee N Donahue, et al.
Nature Communications|May 10, 2024
Author Correction: Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II studyFilipa Lynce, Candace Mainor, Renee N Donahue, et al.
Medrxiv : the Preprint Server for Health Sciences|December 18, 2023
Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II studyFilipa Lynce, Candace Mainor, Renee N Donahue, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 15, 2021
BRE12-158: A Postneoadjuvant, Randomized Phase II Trial of Personalized Therapy Versus Treatment of Physician's Choice for Patients With Residual Triple-Negative Breast CancerBryan P Schneider, Guanglong Jiang, Tarah J Ballinger, et al.
JAMA Oncology|July 10, 2020
Association of Circulating Tumor DNA and Circulating Tumor Cells After Neoadjuvant Chemotherapy With Disease Recurrence in Patients With Triple-Negative Breast Cancer: Preplanned Secondary Analysis of the BRE12-158 Randomized Clinical TrialMilan Radovich, Guanglong Jiang, Bradley A Hancock, et al.
Pageof 11